Instruction for use: Ukidan

Dosage form: Powder lyophilized for the preparation of solution for injection

Active substance: Urokinasum

ATX

B01AD04 Urokinase

Pharmacological group

Fibrinolytics

The nosological classification (ICD-10)

I74 Embolism and arterial thrombosis: Thrombosis of effort (stress); Arterial thrombosis; Arteriothrombosis; Subacute and chronic arterial thrombosis; Subacute thrombosis of peripheral arteries; Postoperative thrombosis; Vascular thrombosis; Vascular embolism; Thrombosis of aortocoronary shunt; Arterial thrombosis; Thrombosis of arteries; Coronary artery thrombosis; Coronary thrombosis; Thrombosis of blood vessels; Thrombosis with ischemic stroke; Thrombosis with general surgical operations; Thrombosis in Oncology Operations; Vascular thrombosis; Thrombus formation in the postoperative period; Thrombotic complications; Thromboembolic diseases; Thromboembolic syndrome; Thromboembolic complication in the postoperative period; Thromboembolism of arteries; Partial vascular thrombosis; Embolism; Embolism of arteries

I82 Embolism and thrombosis of other veins: Recurrent venous thrombosis; Postoperative thrombosis; Venous thrombosis; Acute venous thromboembolism; Recurrent vein thrombosis; Venous thrombosis; Thrombosis of veins of internal organs; Venous thrombosis; Deep vein thrombosis; Thrombosis of blood vessels; Vascular thrombosis; Thrombosis of veins; Deep vein thrombosis; Thromboembolic diseases; Thromboembolism of veins; Severe venous thrombosis; Embolism; Embolism of veins; Thromboembolic complications

Composition and release form

1 bottle with a dry substance for the preparation of the injection solution contains urokinase 5000, 25000, 100000, 500000 or 1000000 IU, complete with a solvent in 2 ml ampoules.

Pharmachologic effect

Mode of action - Fibrinolytic.

Activates the transformation of plasminogen into plasmin.

Pharmacokinetics

After IV introduction, the half-life of the drug in the plasma does not exceed 20 minutes.

Clinical Pharmacology

Increased fibrinolytic activity persists for several hours.

Indication of the drug Ukidan

Acute arterial and venous thrombosis and thromboembolism.

Contraindications

Continuing or recently stopped bleeding; Gastric ulcer diseases; Cerebral thromboses or the presence of predisposing factors for intracranial hemorrhage; Decreased blood clotting; Diabetic hemorrhagic retinopathy; Acute pulmonary edema; Presence of any bleeding tumor; Thrombosis of the vertebral or carotid artery; Subacute endocarditis, atrial fibrillation, mitral stenosis.

Application of pregnancy and breastfeeding

During pregnancy, treatment with the drug may prove ineffective due to the presence in the circulating blood of a high level of natural urokinase inhibitors. Cautiously appoint in the first 18 weeks of pregnancy.

Side effects

Hemorrhages in the perfusion area (especially with infusions exceeding 48 h), gum bleeding, intestinal, purpura (rarely), embolism with fragments of lysis primary thrombus (rare), fever, decrease (moderate) hematocrit.

Interaction

Heparin and drugs that disrupt the function of platelets (non-steroidal anti-inflammatory drugs) increase the risk of bleeding. Antifibrinolytic agents reduce the effect. It is not recommended to mix in one syringe with other drugs.

Dosing and Administration

Powder with active substance is diluted immediately before administration with the applied solvent. For pulmonary embolism and peripheral arterial thrombosis, 300,000 IU is administered by slow (15-30 min) IV infusion followed by continuous perfusion at a dose of 250,000 IU / h for 12 hours, with myocardial infarction in a "shock" dose (2,000,000 IU ) IV, with deep vein thrombosis - 200000 IU by slow (15-30 min) infusion, then 100000 IU / h for 24-72 h by continuous perfusion, with hyphema and hemophthalmia - 5000-25000 IU of the drug, with thrombosis Arteriovenous shunt - directly into the thrombosed shunt (and left in it for 1-2 hours) 5000-25000 IU pr The drug is diluted in physiological saline.

Precautionary measures

Caution should be given to patients over the age of 70 years, in the case of an exfoliating aneurysm, after a recent cardiopulmonary resuscitation, with suspected internal damage.

Storage conditions of the drug Ukidan

Keep out of the reach of children.